Recce Pharmaceuticals Ltd. announced the China National Intellectual Property Administration has formally granted Recce a new family two patent, Copolymer and Method for Treatment of Bacterial Infection, for its anti-infectives, with expiry in 2035. This is the final of Recce?s wholly-owned patents granted for family two, with the Company now patent-protected in all major pharmaceutical markets globally. The Chinese patent claims relate to RECCE 327 (R327) and RECCE 529 (R529), including their methods of manufacture, administration, and application to treat a broad range of common human infections.